[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639738":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":10,"centralContacts":29,"locations":35,"responsibleParty":46,"collaborators":10,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":10,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":10,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"City of Hope Medical Center","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Appendiceal Cancer Cohort",null,"Patients with histologically confirmed appendiceal cancer whose archived tumor tissue specimens and clinicopathologic data are available for integrated DNA methylation and m6A epitranscriptomic profiling.",[13,14],"Diagnostic Test: DNA Methylation Profiling","Diagnostic Test: m6A Epitranscriptomic Profiling",{"label":16,"type":10,"description":17,"interventionNames":18},"Benign Appendix Reference Cohort","Individuals with benign or normal appendix tissue specimens used as non-malignant reference samples for comparison of tumor-associated DNA methylation and m6A epitranscriptomic features.",[13,14],[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DIAGNOSTIC_TEST","DNA Methylation Profiling","Archived tissue specimens undergo DNA methylation profiling to characterize tumor-associated methylation alterations and identify methylation-based molecular features associated with clinicopathologic variables and survival outcomes. The profiling is performed for research purposes only and does not assign treatment.",[9,16],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"m6A Epitranscriptomic Profiling","Archived tissue specimens undergo m6A methylated RNA immunoprecipitation sequencing with matched input RNA sequencing to quantify transcriptome-wide m6A enrichment. The resulting molecular data are used for subtype discovery, m6A score construction, reduced-panel development, and association with clinicopathologic and survival outcomes.",[9,16],[30],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"Ajay Goel","CONTACT","6262184673","ajgoel@coh.org",[36],{"facility":5,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":10,"geoPoint":10,"contacts":43},"RECRUITING","Durate","California","91016","United States","US",[44],{"name":45,"role":32,"phone":33,"phoneExt":10,"email":34},"Ajay Goel, MD",{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100639738","molecular-profiling-for-risk-stratification-in-appendiceal-cancer-100639738",false,"NCT07587268","Molecular Profiling for Risk Stratification in Appendiceal Cancer","Molecular Profiling for Tumor Characterization and Risk Stratification in Patients With Appendiceal Cancer","Inclusion Criteria:\n\n* Patients with histologically confirmed appendiceal adenocarcinoma or appendiceal cancer.\n* Availability of archived tumor tissue suitable for molecular profiling.\n* Availability of tissue for DNA methylation profiling, m6A epitranscriptomic profiling, or both.\n* Availability of relevant clinicopathologic data.\n* Availability of survival or follow-up information when applicable.\n* Age 18 years or older at diagnosis or tissue collection.\n\nExclusion Criteria:\n\n* Insufficient tissue quantity or quality for molecular profiling.\n* Inadequate DNA or RNA quality for sequencing or molecular assay preparation.\n* Missing essential clinicopathologic information required for analysis.\n* Non-appendiceal primary tumor or metastatic tumor to the appendix from another primary site.\n* Patients who do not meet institutional review board or consent requirements, if applicable.","ALL","18 Years",{"count":58,"type":59},400,"ESTIMATED","OBSERVATIONAL","This study investigates integrated epigenetic and epitranscriptomic features of appendiceal cancer using archived tumor tissue specimens from the same patient cohort. The study includes DNA methylation profiling and m6A epitranscriptomic profiling to define molecular subtypes, evaluate associations with clinicopathologic features, and develop molecular risk scores for prognostic stratification. The primary goal is to determine whether DNA methylation- and m6A-based molecular features can complement conventional histopathologic grading and improve risk stratification.",[63,64],"Appendiceal Cancer","Appendiceal Adenocarcinoma",[66,67,68,69,70,71,72,73,74,75,76,77],"Appendiceal cancer","Appendiceal adenocarcinoma","DNA methylation","m6A modification","Multi-omics","MeRIP-seq","Histologic grade;","Epigenomics","Epitranscriptomics","Molecular subtype","Risk stratification","Prognostic biomarker","2026-06-25",{"date":80,"type":81},"2026-06-29","ACTUAL",{"date":83,"type":81},"2026-05-01",{"date":85,"type":59},"2027-01-01",{"name":5,"class":6},1]